SCHEMBL30516340

SCHEMBL30516340

CN1CCN(c2cccc3c2cc(C(F)(F)F)n3Cc2ccc(Cl)c(F)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.41
CCR2 P41597 2/20 0.38
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
GRM2 Q14416 1/20 0.36
HTR6 P50406 4/20 0.36
HTR1A P08908 2/20 0.36
DRD4 P21917 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
MAPK1 P28482 1/20 0.35
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
HTR3E A5X5Y0 1/20 0.34
HTR3B O95264 1/20 0.34
HTR3A P46098 1/20 0.34
HTR3D Q70Z44 1/20 0.34
HTR3C Q8WXA8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21291586 1.00 SOS1 (0.41) SOS1CCR2DRD2DRD3GRM2
SCHEMBL30516341 0.92 CCR2 (0.46) SOS1CCR2DRD2DRD3HTR6
SCHEMBL21291615 0.92 CCR2 (0.46) SOS1CCR2DRD2DRD3HTR6
SCHEMBL21291618 0.91 SOS1 (0.38) SOS1DRD2HTR6HTR1AHTR2A
SCHEMBL30516346 0.91 SOS1 (0.38) SOS1DRD2HTR6HTR1AHTR2A
SCHEMBL21291620 0.88 HTR6 (0.46) SOS1CCR2DRD2DRD3HTR6
SCHEMBL30516355 0.88 HTR6 (0.46) SOS1CCR2DRD2DRD3HTR6
Hydrochloric Acid SCHEMBL30516375 0.87 HTR6 (0.45) SOS1CCR2DRD2DRD3HTR6
SCHEMBL21291591 0.87 HTR6 (0.48) DRD2HTR6
SCHEMBL30516335 0.87 HTR6 (0.48) DRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN claimed
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2025-06-03 US disclosed
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS Adamed Pharma S.A (PL) 2024-08-29 US disclosed
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists ADAMED PHARMA S.A. (PL) 2024-05-14 US disclosed
CN-112041300-B Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists 阿达梅德制药公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12319682-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR6, HTR2C SOS1 3794/4885CCR2 2143/4885DRD2 20/4885
US-11981668-B2 Indole and benzimidazole derivatives as dual 5-HT2A and 5-HT6 receptor antagonists HTR2A, HTR2C, HTR6 SOS1 2962/4885CCR2 1238/4885DRD2 20/4885
US-20240287056-A1 INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS HTR2A, HTR6, HTR2C SOS1 3801/4885CCR2 1921/4885DRD2 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.